Don't Overlook Unexpected, but Risky, Diagnoses
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L. -
FOCUSED PRACTICE in HOSPITAL MEDICINE Maintenance of Certification (MOC) Examination Blueprint
® FOCUSED PRACTICE IN HOSPITAL MEDICINE Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Purpose of the Hospital Medicine MOC exam Hospital Medicine MOC exam blueprint The MOC exam is designed to evaluate the knowledge, Based on feedback from physicians that MOC assessments diagnostic reasoning, and clinical judgment skills expected of should better reflect what they see in practice, in 2016 the the certified hospitalist in the broad domain of the discipline. American Board of Internal Medicine (ABIM) invited all certified The exam emphasizes diagnosis and management of prevalent hospitalists and those enrolled in the focused practice program conditions, particularly in areas where practice has changed to provide ratings of the relative frequency and importance of in recent years. As a result of the blueprint review by ABIM blueprint topics in practice. diplomates, the MOC exam places less emphasis on rare This review process, which resulted in a new MOC exam conditions and focuses more on situations in which physician blueprint, will be used on an ongoing basis to inform and intervention can have important consequences for patients. update all MOC assessments created by ABIM. No matter For conditions that are usually managed by other specialists, what form ABIM’s assessments ultimately take, they will need the focus is on recognition rather than on management. The to be informed by front-line clinicians sharing their perspective exam is developed jointly by the ABIM and the American on what is important to know. Board of Family Medicine. A sample of over 100 hospitalists, similar to the total invited Exam format population of hospitalists in age, gender, geographic region, and time spent in direct patient care, provided the blueprint The traditional 10-year MOC exam is composed of 220 single- topic ratings. -
Adverse Drug Reactions Sample Chapter
Sample copyright Pharmaceutical Press www.pharmpress.com 5 Drug-induced skin reactions Anne Lee and John Thomson Introduction Cutaneous drug eruptions are one of the most common types of adverse reaction to drug therapy, with an overall incidence rate of 2–3% in hos- pitalised patients.1–3 Almost any medicine can induce skin reactions, and certain drug classes, such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and antiepileptics, have drug eruption rates approaching 1–5%.4 Although most drug-related skin eruptions are not serious, some are severe and potentially life-threatening. Serious reac- tions include angio-oedema, erythroderma, Stevens–Johnson syndrome and toxic epidermal necrolysis. Drug eruptions can also occur as part of a spectrum of multiorgan involvement, for example in drug-induced sys- temic lupus erythematosus (see Chapter 11). As with other types of drug reaction, the pathogenesis of these eruptions may be either immunological or non-immunological. Healthcare professionals should carefully evalu- ate all drug-associated rashes. It is important that skin reactions are identified and documented in the patient record so that their recurrence can be avoided. This chapter describes common, serious and distinctive cutaneous reactions (excluding contact dermatitis, which may be due to any external irritant, including drugs and excipients), with guidance on diagnosis and management. A cutaneous drug reaction should be suspected in any patient who develops a rash during a course of drug therapy. The reaction may be due to any medicine the patient is currently taking or has recently been exposed to, including prescribed and over-the-counter medicines, herbal or homoeopathic preparations, vaccines or contrast media. -
Mantke, Peitz, Surgical Ultrasound -- Index
419 Index A esophageal 218 Anorchidism 376 gallbladder 165 Aorta 364–366 A-mode imaging 97 gastric 220 abdominal aneurysm (AAA) AAA (abdominal aortic aneurysm) metastasis 142 20–21, 364, 366 20–21, 364, 366 pancreatic 149, 225 dissection 364, 366 Abdominal wall Adenofibroma, breast 263 perforation 366 abscess 300–301 Adenoma pseudoaneurysm 364 diagnostic evaluation 297 adrenal 214 Aortic rupture 20 hematoma 73, 300, 305 colorectal 231, 232 Aplasia, muscular 272 rectus sheath 297–300 duodenal papilla 229, 231 Appendicitis 1–4 hernia 300, 302–304 gallbladder 165 consequences for surgical indications for sonography 297 hepatic 54, 58, 141 treatment 2 seroma 298, 300, 305 multiple 141 sonographic criteria 1 trauma 297–300 parathyroid 213 Archiving 418 Abortion, tubal 30 renal 241 Arteriosclerosis 346, 348 Abscess thyroid 202–203 carotid artery 335, 337, 338 abdominal wall 300–301 Adenomyomatosis 8, 164, 165 plaque 337, 338, 345, 367, 370 causes 301 Adrenal glands 214–216 Arteriovenous (AV) malformation amebic 138 adenoma 214 139, 293, 326–329 breast 264 carcinoma 214 Artery chest wall 173, 178 cyst 214 carotid 334–339 diverticular 120, 123 hematoma 214 aneurysm 338 drainage 85–88, 93 hemorrhage 214 arteriosclerosis 335 hepatic 6, 138, 398 hyperplasia 214 plaque characteristics inflammatory bowel disease limpoma/myelipoma 214 337, 338, 345 116, 119 metastases 214 bifurcation 334, 337 intramural 5 sonographic criteria 214 bulb 339 lung 183, 186, 190 tuberculosis 214 dissection 338, 339, 346 pancreatic 11 Advanced dynamic flow (ADF) sonographic -
Clinical Excellence Series Volume VI an Evidence-Based Approach to Infectious Disease
Clinical Excellence Series n Volume VI An Evidence-Based Approach To Infectious Disease Inside The Young Febrile Child: Evidence-Based Diagnostic And Therapeutic Strategies Pharyngitis In The ED: Diagnostic Challenges And Management Dilemmas HIV-Related Illnesses: The Challenge Of Emergency Department Management Antibiotics In The ED: How To Avoid The Common Mistake Of Treating Not Wisely, But Too Well Brought to you exclusively by the publisher of: An Evidence-Based Approach To Infectious Disease CEO: Robert Williford President & Publisher: Stephanie Ivy Associate Editor & CME Director: Jennifer Pai • Associate Editor: Dorothy Whisenhunt Director of Member Services: Liz Alvarez • Marketing & Customer Service Coordinator: Robin Williford Direct all questions to EB Medicine: 1-800-249-5770 • Fax: 1-770-500-1316 • Non-U.S. subscribers, call: 1-678-366-7933 EB Medicine • 5550 Triangle Pkwy Ste 150 • Norcross, GA 30092 E-mail: [email protected] • Web Site: www.ebmedicine.net The Emergency Medicine Practice Clinical Excellence Series, Volume Volume VI: An Evidence-Based Approach To Infectious Disease is published by EB Practice, LLC, d.b.a. EB Medicine, 5550 Triangle Pkwy Ste 150, Norcross, GA 30092. Opinions expressed are not necessarily those of this publication. Mention of products or services does not constitute endorsement. This publication is intended as a general guide and is intended to supplement, rather than substitute, professional judgment. It covers a highly technical and complex subject and should not be used for making specific medical decisions. The materials contained herein are not intended to establish policy, procedure, or standard of care. Emergency Medicine Practice, The Emergency Medicine Practice Clinical Excellence Series, and An Evidence-Based Approach To Infectious Disease are trademarks of EB Practice, LLC, d.b.a. -
Consultative Comanagement (15%)
Consultative Comanagement (15%) Focused Practice in Hospital Medicine (FPHM) Where Can I Find this topic Blueprint Topic: covered in MKSAP 17? Perioperative Medicine (12.5%) Cardiology Endocarditis prophylaxis MKSAP 17 Cardiovascular Medicine Perioperative risk-stratification MKSAP 17 General Internal Medicine Perioperative arrhythmias MKSAP 17 Cardiovascular Medicine; MKSAP 17 General Internal Medicine Pulmonology Perioperative asthma management MKSAP 17 Pulmonary and Critical Care Medicine; MKSAP 17 General Internal Medicine Perioperative chronic obstructive pulmonary disease MKSAP 17 Pulmonary and Critical Care management Medicine Postoperative hypoxia MKSAP 17 Pulmonary and Critical Care Medicine Hematology Perioperative anticoagulation and antiplatelet therapy MKSAP 17 General Internal Medicine Perioperative deep venous thrombosis prophylaxis MKSAP 17 General Internal Medicine Endocrinology Perioperative diabetes mellitus management MKSAP 17 General Internal Medicine Perioperative stress-dose corticosteroid management MKSAP 17 General Internal Medicine Perioperative thyroid management and thyroid storm MKSAP 17 General Internal Medicine; MKSAP 17 Endocrinology and Metabolism Perioperative and postoperative infections MKSAP 17 Infectious Disease Neurology Postoperative delirium MKSAP 17 Neurology Compressive neuropathies MKSAP 17 Neurology Pregnancy (2.5%) Hypertension in pregnancy (pre-eclampsia and eclampsia) MKSAP 17 Nephrology MKSAP 17 Pulmonary and Critical Care Asthma and pregnancy Medicine Hyperthyroidism during pregnancy or -
Pharmaceuticals Appendix
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1 -
Safety and Efficacy of Ceftaroline Fosamil in the Management of Community-Acquired Bacterial Pneumonia Heather F
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Scholarly Papers 2014 Safety and Efficacy of Ceftaroline Fosamil in the Management of Community-Acquired Bacterial Pneumonia Heather F. DeBellis Kimberly L. Barefield Philadelphia College of Osteopathic Medicine, [email protected] Follow this and additional works at: https://digitalcommons.pcom.edu/scholarly_papers Part of the Medicine and Health Sciences Commons Recommended Citation DeBellis, Heather F. and Barefield, Kimberly L., "Safety and Efficacy of Ceftaroline Fosamil in the Management of Community- Acquired Bacterial Pneumonia" (2014). PCOM Scholarly Papers. 1913. https://digitalcommons.pcom.edu/scholarly_papers/1913 This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by an authorized administrator of DigitalCommons@PCOM. For more information, please contact [email protected]. Open Access: Full open access to Clinical Medicine Reviews this and thousands of other papers at http://www.la-press.com. in Therapeutics Safety and Efficacy of Ceftaroline Fosamil in the Management of Community- Acquired Bacterial Pneumonia Heather F. DeBellis and Kimberly L. Tackett South University School of Pharmacy, Savannah, GA, USA. ABSTR ACT: Ceftaroline fosamil is a new fifth-generation cephalosporin indicated for the treatment of community-acquired bacterial pneumonia (CABP). It possesses antimicrobial effects against both Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), but not against anaerobes. Organisms covered by this novel agent that are commonly associated with CABP are Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Klebsiella pneumoniae; however, ceftaroline fosamil lacks antimicrobial activity against Pseudomonas and Acinetobacter species. -
Methadone and Buprenorphine: Clinical Impact of Drug Interactions
11/03/2014 Methadone and Buprenorphine: Clinical Impact of Drug Interactions Elinore F. McCance-Katz, MD, PhD Disclosures None Adverse Drug Interactions • Accidents: leading cause of death in the USA in those aged 1–44 with highest rates in 25–44 y.o. • Poisoning: a leading cause of accidental deaths in the US – 145% increase in 1999–2007 – Opioids most frequently named drugs in poisonings • DDIs: a leading cause of accidental poisoning deaths in the USA (CDC, 2011) – Those exposed to DDIs between CYP450-metabolized opioids and other medications have higher medical costs (Summers et al, 2011) 1 11/03/2014 Underlying Reasons for DDIs • Many with opioid dependence have co-occurring medical and / or mental disorders • Patients believe prescribed drugs are ‘safe’ • Lack of patient education about adverse events that can occur • May not understand need to take as prescribed • Sharing / selling Pathophysiology of DDIs • Pharmacokinetic (PK) – What you do to the drug (or not) – With PK interactions, one drug causes an alteration in the concentration of another drug increasing risks of side effects or reduced effectiveness of the drug • Pharmacodynamic (PD) – What the drug or drugs do to you – With PD interactions, two drugs have additive effects or antagonistic effects Pharmacodynamic Interactions • PK interactions may have associated PD consequences • PD interactions can occur in the absence of a PK interaction • Two drugs with similar pharmacological characteristics interact synergistically – Increases potential toxicity of drug – Opioids -
Organ System % of Exam Content Diseases/Disorders
Organ System % of Exam Diseases/Disorders Content Cardiovascular 16 Cardiomyopathy Congestive Heart Failure Vascular Disease Dilated Hypertension Acute rheumatic fever Hypertrophic Essential Aortic Restrictive Secondary aneurysm/dissection Conduction Disorders Malignant Arterial Atrial fibrillation/flutter Hypotension embolism/thrombosis Atrioventricular block Cardiogenic shock Chronic/acute arterial Bundle branch block Orthostasis/postural occlusion Paroxysmal supraventricular tachycardia Ischemic Heart Disease Giant cell arteritis Premature beats Acute myocardial infarction Peripheral vascular Ventricular tachycardia Angina pectoris disease Ventricular fibrillation/flutter • Stable Phlebitis/thrombophlebitis Congenital Heart Disease • Unstable Venous thrombosis Atrial septal defect • Prinzmetal's/variant Varicose veins Coarctation of aorta Valvular Disease Patent ductus arteriosus Aortic Tetralogy of Fallot stenosis/insufficiency Ventricular septal defect Mitral stenosis/insufficiency Mitral valve prolapse Tricuspid stenosis/insufficiency Pulmonary stenosis/insufficiency Other Forms of Heart Disease Acute and subacute bacterial endocarditis Acute pericarditis Cardiac tamponade Pericardial effusion Pulmonary 12 Infectious Disorders Neoplastic Disease Pulmonary Acute bronchitis Bronchogenic carcinoma Circulation Acute bronchiolitis Carcinoid tumors Pulmonary embolism Acute epiglottitis Metastatic tumors Pulmonary Pulmonary nodules hypertension Croup Obstructive Pulmonary Cor pulmonale Influenza Disease Restrictive Pertussis Asthma Pulmonary -
Ceftaroline in Complicated Skin and Skin-Structure Infections
Infection and Drug Resistance Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Ceftaroline in complicated skin and skin-structure infections Paul O Hernandez1 Abstract: Ceftaroline is an advanced-generation cephalosporin antibiotic recently approved by Sergio Lema2 the US Food and Drug Administration for the treatment of complicated skin and skin-structure Stephen K Tyring3 infections (cSSSIs). This intravenous broad-spectrum antibiotic exerts potent bactericidal activity Natalia Mendoza2,4 by inhibiting bacterial cell wall synthesis. A high affinity for the penicillin-binding protein 2a (PBP2a) of methicillin-resistant Staphylococcus aureus (MRSA) makes the drug especially 1University of Texas School of Medicine at San Antonio, beneficial to patients with MRSA cSSSIs. Ceftaroline has proved in multiple well-conducted San Antonio, TX, 2Woodhull clinical trials to have an excellent safety and efficacy profile. In adjusted doses it is also recom- Medical and Mental Health Center, mended for patients with renal or hepatic impairment. Furthermore, the clinical effectiveness Brooklyn, NY, 3Department of Dermatology, University of Texas and high cure rate demonstrated by ceftaroline in cSSSIs, including those caused by MRSA Health Science Center at Houston, and other multidrug-resistant strains, warrants its consideration as a first-line treatment option 4 Houston, TX, USA; Department of for cSSSIs. This article reviews ceftaroline and its pharmacology, efficacy, and safety data to Dermatology, El -
Peritonsillar Abscess NICHOLAS J
Peritonsillar Abscess NICHOLAS J. GALIOTO, MD, Broadlawns Medical Center, Des Moines, Iowa Peritonsillar abscess is the most common deep infection of the head and neck, occurring primarily in young adults. Diagnosis is usually made on the basis of clinical presentation and examination. Symptoms and findings generally include fever, sore throat, dysphagia, trismus, and a “hot potato” voice. Drainage of the abscess, antibiotic therapy, and supportive therapy for maintaining hydration and pain control are the cornerstones of treatment. Most patients can be managed in the outpatient setting. Peritonsillar abscesses are polymicrobial infections, and antibiotics effec- tive against group A streptococcus and oral anaerobes should be first-line therapy. Corticosteroids may be helpful in reducing symptoms and speeding recovery. Promptly recognizing the infection and initiating therapy are important to avoid potentially serious complications, such as airway obstruction, aspiration, or extension of infection into deep neck tissues. Patients with peritonsillar abscess are usually first encountered in the primary care outpatient setting or in the emergency department. Family physicians with appropriate training and experience can diagnose and treat most patients with peritonsillar abscess. (Am Fam Physician. 2017;95(8):501-506. Copyright © 2017 American Acad- emy of Family Physicians.) CME This clinical content eritonsillar abscess is the most Etiology conforms to AAFP criteria common deep infection of the Peritonsillar abscess has traditionally been for continuing medical education (CME). See head and neck, with an annual regarded as the last stage of a continuum CME Quiz Questions on incidence of 30 cases per 100,000 that begins as an acute exudative tonsil- page 483. Ppersons in the United States.1-3 This infec- litis, which progresses to a cellulitis and Author disclosure: No rel- tion can occur in all age groups, but the eventually abscess formation.